|Articles|April 1, 1998

Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach
Volume 4
Issue 4 Suppl

Introduction: Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach

Download PDF: Introduction: Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach

Articles in this issue

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Coronary Heart Disease in the United States

over 28 years ago

Article

Mechanisms of Acute Coronary Events

over 28 years ago

Article

Primary Prevention

over 28 years ago

Article

Pravastatin Event Reduction Analysis

over 28 years ago

Article

Secondary Prevention

over 28 years ago

Article

Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?

over 28 years ago

Article

Methods and Mindsets in Pharmacoeconomics

over 28 years ago

Article

Issues and Controversies in Pharmacoeconomics

over 28 years ago

Article

Pharmacoeconomics Perspectives: Payers, Providers, and Patients

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Introduction: Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Introduction: Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

AI Chatbots Score Below 28% on Colorectal Cancer Questions

5 Notable FDA Approvals From the First Half of 2026

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma